TPST vs ALAR Comparison

Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.

Alarum Technologies Ltd is a software-as-a-service (SaaS) provider operating mainly in the web data collection market, offering web data collection and a private internet browsing platform. The company's Web Data Collection products offer secure, fast, and anonymous IP Proxy Network Solutions & Services, or IPPN or IPPN Solutions, to its business customers which, in turn, enables them to anonymously and securely browse the internet as well as to collect data from any publicly available source on the web, for their business purpose. The company operates in one segment: web data collection. Geographically, it derives maximum revenue from China, followed by the United States, Europe, Hong Kong, Asia-Pacific, U.K. Virgin Islands, Israel, United Arab Emirates, Middle East & Africa and other.